Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$1.30 -0.10 (-7.14%)
(As of 12/20/2024 04:04 PM ET)

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$1.29
$1.40
50-Day Range
$0.89
$3.39
52-Week Range
$0.87
$10.80
Volume
2,827 shs
Average Volume
21,911 shs
Market Capitalization
$6.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

Analyzing Zentalis Pharmaceuticals (NASDAQ:ZNTL) & Orgenesis (NASDAQ:ORGS)
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
Orgenesis Expands Board with Three New Appointments
Orgenesis commences trading on OTCQX Best Market
Orgenesis Commences Trading on OTCQX® Best Market
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $4.08 on January 1st, 2024. Since then, ORGS stock has decreased by 68.1% and is now trading at $1.30.
View the best growth stocks for 2024 here
.

Orgenesis Inc. (NASDAQ:ORGS) released its earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share for the quarter, missing the consensus estimate of $0.60 by $2.10. The business earned $6.98 million during the quarter.

Orgenesis shares reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
150
Year Founded
2008

Profitability

Net Income
$-55,360,000.00
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%

Debt

Sales & Book Value

Annual Sales
$662,000.00
Book Value
($6.58) per share

Miscellaneous

Free Float
4,527,000
Market Cap
$6.24 million
Optionable
Optionable
Beta
1.31

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners